5a2l: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of scFv-SM3 in complex with APD-CGalNAc-RP== | ==Crystal structure of scFv-SM3 in complex with APD-CGalNAc-RP== | ||
<StructureSection load='5a2l' size='340' side='right' caption='[[5a2l]], [[Resolution|resolution]] 1.79Å' scene=''> | <StructureSection load='5a2l' size='340' side='right'caption='[[5a2l]], [[Resolution|resolution]] 1.79Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5a2l]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5A2L OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5A2L FirstGlance]. <br> | <table><tr><td colspan='2'>[[5a2l]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5A2L OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5A2L FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=A2G:N-ACETYL-2-DEOXY-2-AMINO-GALACTOSE'>A2G</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=A2G:N-ACETYL-2-DEOXY-2-AMINO-GALACTOSE'>A2G</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5a2i|5a2i]], [[5a2j|5a2j]], [[5a2k|5a2k]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5a2i|5a2i]], [[5a2j|5a2j]], [[5a2k|5a2k]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5a2l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5a2l OCA], [http://www.rcsb.org/pdb/explore.do?structureId=5a2l RCSB], [http://www.ebi.ac.uk/pdbsum/5a2l PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5a2l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5a2l OCA], [http://pdbe.org/5a2l PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5a2l RCSB], [http://www.ebi.ac.uk/pdbsum/5a2l PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5a2l ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 15: | Line 16: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 5a2l" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Antibody 3D structures|Antibody 3D structures]] | |||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | |||
[[Category: Lk3 transgenic mice]] | |||
[[Category: Asensio, J L]] | [[Category: Asensio, J L]] | ||
[[Category: Avenoza, A]] | [[Category: Avenoza, A]] | ||
Revision as of 11:50, 26 June 2019
Crystal structure of scFv-SM3 in complex with APD-CGalNAc-RPCrystal structure of scFv-SM3 in complex with APD-CGalNAc-RP
Structural highlights
Publication Abstract from PubMedThe structural features of MUC1-like glycopeptides bearing the Tn antigen (alpha-O-GalNAc-Ser/Thr) in complex with an anti MUC-1 antibody are reported at atomic resolution. For the alpha-O-GalNAc-Ser derivative, the glycosidic linkage adopts a high-energy conformation, barely populated in the free state. This unusual structure (also observed in an alpha-S-GalNAc-Cys mimic) is stabilized by hydrogen bonds between the peptidic fragment and the sugar. The selection of a particular peptide structure by the antibody is thus propagated to the carbohydrate through carbohydrate/peptide contacts, which force a change in the orientation of the sugar moiety. This seems to be unfeasible in the alpha-O-GalNAc-Thr glycopeptide owing to the more limited flexibility of the side chain imposed by the methyl group. Our data demonstrate the non-equivalence of Ser and Thr O-glycosylation points in molecular recognition processes. These features provide insight into the occurrence in nature of the APDTRP epitope for anti-MUC1 antibodies. Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody.,Martinez-Saez N, Castro-Lopez J, Valero-Gonzalez J, Madariaga D, Companon I, Somovilla VJ, Salvado M, Asensio JL, Jimenez-Barbero J, Avenoza A, Busto JH, Bernardes GJ, Peregrina JM, Hurtado-Guerrero R, Corzana F Angew Chem Int Ed Engl. 2015 Jun 26. doi: 10.1002/anie.201502813. PMID:26118689[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Large Structures
- Lk3 transgenic mice
- Asensio, J L
- Avenoza, A
- Bernardes, G J.L
- Busto, J H
- Castro-Lopez, J
- Companon, I
- Corzana, F
- Hurtado-Guerrero, R
- Jimenez-Barbero, J
- Madariaga, D
- Martinez-Saez, N
- Peregrina, J M
- Salvado, M
- Somovilla, V J
- Valero-Gonzalez, J
- Antibody
- Conformation analysis
- Fusion protein
- Glycopeptide
- Immune system
- Molecular recognition
- Peptide binding protein